Recruiting
Phase 2

Surface Electrical Stimulation

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06161506

Conditions

Urinary Urge Incontinence

Stress Urinary Incontinence

Prostatic Hyperplasia

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Elidah Device

Study Details

Brief summary:

Background:

Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.

Objective:

To see if the Elidah device can reduce urinary incontinence after prostate treatment.

Eligibility:

Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.

Design:

Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.

The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.

Participants will be given an Elidah device and taught how to use it at home.

They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.

Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.

Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.

Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.

Participants will complete 15-minute questionnaires.

Conditions

Urinary Urge Incontinence

Stress Urinary Incontinence

Prostatic Hyperplasia

Study ID

NCT06161506

Start date

Feb 15, 2024

Status verified date

Jul 20, 2026

Completion date

Mar 1, 2028

Anticipated

Primary completion date

Dec 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Not accepted

  • INCLUSION CRITERIA:
  • Participants must be male.
  • Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.
  • Participants must have at least one of the following types of urinary incontinence:

  • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing
  • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
  • Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.
  • Participants must be able to read and write in English.
  • Age >= 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
  • Ability to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Change of therapy for prostate cancer planned during the study intervention.
  • History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.
  • Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (>= 4 UTIs within the 12 months prior to the study treatment initiation).
  • History of complete denervation of the pelvic floor.
  • Severe obesity (body mass index \[BMI\] >35).
  • Pelvic pain/painful bladder syndrome.
  • Metal implant in the abdominal or pelvic area.
  • History of chronic cough with ongoing symptoms
  • An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.
  • History of epilepsy.
  • History of underlying neurologic/neuromuscular disorder that could contribute to urinary incontinence.
  • Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.
  • Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.

Study Design

Enrollment

41 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: 1/Elidah Device

Elidah device application.

Interventions

Elidah Device

The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.

Primary outcome measure

  • To describe the efficacy of the Elidah device treatment on male urinary incontinence [ Time Frame: Baseline and within 2 weeks after completing treatment ]

Central Contacts and Locations

Central contacts

Debbie-Ann N Nathan, R.N.

(240) 858-3103dnathan@mail.nih.gov

Deborah E Citrin, M.D.

(240) 760-6206citrind@mail.nih.gov

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

National Cancer Institute Referral Office

888-624-1937

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Jul 24, 2026

Last verified

Jul 20, 2026

Keywords

  • Elidah Device
  • Urinary Incontinence
  • Prostate Cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-07-24.